Companion Diagnostics Development Services
Use the Novodiax polymerized horseradish peroxidase (polyHRP) signal amplification technology (ihcDirect) and conjugate it directly to your humanized antibody-of-choice to enable rapid, sensitive IHC testing. Jumpstart your early humanized antibody-to-human tissue testing or ADME/toxicology studies to fail candidates early.
Details
Current methods of CDx development force pharmaceutical antibody developers to modify the primary antibody in order to gain sensitivity and to fit into the current schemes of FFPE testing. Direct conjugation is better because your antibodies can be conjugated directly onto our pHRP system in an unmodified form. Thus, this next generation of immunoassay test saves you time, eliminates bias, and reduces the potential for cross-reactivity with secondary antibodies.
Our sensitive antigen detection system is perfect for rapid, high-precision IHC and ELISA testing and holds potential for future cytology test protocols. This approach can thus speed up development (biomarker identification, clone selection, validation and profiling, tissue cross reactivity testing, etc.) and provides high quality IHC results in as little as 10 minutes using frozen tissues!
We can provide custom support for your specific needs, or even partner with you through the entire development process.
Applications
Our ihcDirect technology can be readily adapted to companion diagnostics for a wide variety of antibody therapies:
- Antibody Drug Conjugates (ADC)
- Antibody Dependent Cell-Mediated Cytotoxicity (ADCC)
- Signal Transduction blockage
- Immune check point blockage
- … and more
Customer reviews
No reviews were found for Companion Diagnostics Development Services. Be the first to review!